z-immunology-spotlight

The anti-IgE therapy omalizumab improves asthma control and reduces exacerbations in patients with moderate-to-severe allergic asthma. However, it has been suggested that omalizumab should be reserved for highly allergic...

Pulmonary disease is a frequent acute and chronic manifestation in sickle cell disease (SCD), presenting high morbidity and mortality. This study sought to identify the prevalence and association of asthma, allergic...

“The level of asthma control among pediatric patients improved during the COVID-19 lockdown period, likely because of reduced exposure to typical asthma triggers due to the confinement,” the authors of a recent study write. “The...

Asthma affects approximately 1 in 10 children and the prevalence of asthma has dramatically increased within a generation, strongly implicating lifestyle and/or environmental causes, explain the authors of a recent study. Black...

Since approximately 5% to 10% of patients with asthma have severe disease, there is an urgent need for improved management and treatment approaches and biologic therapies are an increasingly important treatment option, according...

Childhood and onset of allergic asthma are strongly associated, but only a few studies have analyzed incidence of asthma from childhood to late adulthood in relation to allergy. Researchers found the incidence of allergic asthma...

The National Institutes of Health (NIH) recently announced 19 recommendations for the diagnosis, management, and treatment of asthma in six key area, including four new recommendations targeting allergic asthma. The new...